The stop-strengthening variant in PMVK was associated with increased risk of Type 1 diabetes while the stop-strengthening variant in VPS53 was associated with a protective effect against anxiety disorders (Fig. 4, Supplementary Fig. 6, Table 1, and Supplementary Table 3). Here, VPS53 is linked to type 1 diabetes mellitus.